HALOZYME THERAPEUTICS, INC. Stock Repurchased During Period, Shares
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- HALOZYME THERAPEUTICS, INC. stock repurchased during period, shares for the quarter ending 2023-12-31 was 0.00 shares.
- HALOZYME THERAPEUTICS, INC. stock repurchased during period, shares for the quarter ending 2023-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. stock repurchased during period, shares for the quarter ending 2023-06-30 was 0.00 shares.
- HALOZYME THERAPEUTICS, INC. stock repurchased during period, shares for the quarter ending 2023-03-31 was 4.17M shares.
- HALOZYME THERAPEUTICS, INC. stock repurchased during period, shares for fiscal 2023 was 4.17M shares, a 7.44% decline from fiscal 2022.
- HALOZYME THERAPEUTICS, INC. stock repurchased during period, shares for fiscal 2022 was 4.50M shares, a 3.21% decline from fiscal 2021.
- HALOZYME THERAPEUTICS, INC. stock repurchased during period, shares for fiscal 2021 was 4.65M shares, a 28.55% decline from fiscal 2020.
- HALOZYME THERAPEUTICS, INC. stock repurchased during period, shares for fiscal 2020 was 6.51M shares.
| Period end | Stock Repurchased During Period, Shares 3 month | Stock Repurchased During Period, Shares 12 month |
|---|---|---|
| 2023-12-31 | 0.00 shares 10-K · filed 2024-02-20 | 4.17M shares 10-K · filed 2024-02-20 |
| 2023-09-30 | 0.00 shares 10-K · filed 2024-02-20 | 4.17M shares derived: sum of 4 quarters · filed 2024-02-20 |
| 2023-06-30 | 0.00 shares 10-K · filed 2024-02-20 | 8.67M shares derived: sum of 4 quarters · filed 2024-02-20 |
| 2023-03-31 | 4.17M shares 10-K · filed 2024-02-20 | 8.67M shares derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-12-31 | 0.00 shares 10-K · filed 2023-02-21 | 4.50M shares 10-K · filed 2023-02-21 |
| 2022-09-30 | 4.50M shares 10-K · filed 2023-02-21 | 4.77M shares derived: sum of 4 quarters · filed 2023-02-21 |
| 2022-06-30 | 0.00 shares 10-K · filed 2023-02-21 | 1.84M shares derived: sum of 4 quarters · filed 2023-02-21 |
| 2022-03-31 | 0.00 shares 10-K · filed 2023-02-21 | 2.87M shares derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-12-31 | 273.21K shares 10-K · filed 2022-02-22 | 4.65M shares 10-K · filed 2022-02-22 |
| 2021-09-30 | 1.56M shares 10-K · filed 2022-02-22 | 5.47M shares derived: sum of 4 quarters · filed 2022-02-22 |
| 2021-06-30 | 1.04M shares 10-K · filed 2022-02-22 | 6.04M shares derived: sum of 4 quarters · filed 2022-02-22 |
| 2021-03-31 | 1.78M shares 10-K · filed 2022-02-22 | 5.09M shares derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-12-31 | 1.10M shares 10-K · filed 2021-02-23 | 6.51M shares 10-K · filed 2021-02-23 |
| 2020-09-30 | 2.13M shares 10-K · filed 2021-02-23 | |
| 2020-06-30 | 88.31K shares 10-K · filed 2021-02-23 | |
| 2020-03-31 | 3.19M shares 10-K · filed 2021-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |